How did it start?
The "Joe Tippens Protocol" has been copied, adapted, and debated by thousands of people online.
Fenbendazole was introduced as a veterinary medicine around 1977. It is a member of the benzimidazole class of drugs. This class of medicines specifically targets microtubules, cellular structures critical for cell division. Fenbendazole disrupts cancer’s ability to maintain cellular integrity.
Fenbendazole for animals is marketed and sold for veterinary use under several names, including:
Panacur
Safe-Guard
Axilur
Each of these formulations was developed to target different animal species and to adapt to distinct farming methods, thereby expanding their applications in veterinary medicine.
The global online discussion about using Fenbendazole to treat certain types of cancer started around 2016. Early that year, a man from Oklahoma, Joe Tippens, was diagnosed with late-stage small-cell lung cancer. Despite a life-ending prognosis, Joe continued traditional cancer treatment but sought alternative methods to fight the disease and restore his health. He learned of cancer patients who had self-administered Fenbendazole. Joe added the 222mg packet of dog dewormer to his daily routine, taking a dose comfortable for him. He also took vitamin E, CBD oil, and curcumin supplements daily.
Pairing Fenbendazole with supplements can enhance the drug’s effects, support immune system function, or reduce inflammation. Patients want to improve the effectiveness of their treatment, even if the benefit is minor. We highly recommend certain supplements and additional ingredients.
During his treatment, Joe carefully documented his experiences and shared them on his public blog titled My Cancer Story, making the information accessible to everyone. The following year, in 2017, his PET scans showed no active cancer in his body, leading to the remission of his stage four lung cancer. As of February 2, 2026, he remains alive and well.
Building upon his openness, Joe consistently disclosed his exact protocol and provided open online discussions. Since then, the “Joe Tippens Protocol” has been copied, adapted, and debated by thousands of people online. His approach was self-directed and involved considerable personal risk. At no point did Joe profit from sharing his information.
As a result of Joe’s transparency, many cancer patients, like Joe, self-administer Fenbendazole in powdered form. A typical dose involves consuming a 222mg powdered packet, which is sold as a treatment for small animals. Joe’s protocol consisted of taking 222mg of Panacur C, marketed for dogs, for three consecutive days, followed by four days without the drug; this approach is referred to as cycling. Some users report altering either the timing or the amount of each dose. (see protocols)
Expanding on this approach, many people add supplements or adjust their cycling, alternating on- and off-days. Long-term drug use can stress the body, including the liver, kidneys, and digestive system. Cycling—using a drug for a set period, then taking a break—allows the body time to recover from any potential stress.
Given these variables, we recommend that anyone self-administering Fenbendazole work with medically trained professionals, carefully tracking ingested amounts, interactions, and daily outcomes, and consider breaks in administration to monitor progress and side effects.
Case Joe Tippens
Fenbendazole garnered global attention as a potential anti-cancer therapy following the complete recovery success story of Joe Tippens, who was diagnosed with small-cell lung cancer. At the time, Tippens was participating in a clinical trial for a novel anticancer drug. Meanwhile, under the guidance of a veterinarian, Tippens began self-administering 222 mg fenbendazole orally, along with vitamin E supplements, CBD oil, and bioavailable curcumin. After three months of self-administration, a PET scan revealed no detectable cancer cells in his body. Notably, Tippens was the only patient cured of cancer among the 1,000+ clinical trial participants (3). While the Joe Tippens case is compelling, it remains an anecdotal report. It underscores the need for rigorous clinical trials to validate the efficacy and safety of fenbendazole as an anti-cancer therapy.
*ANTICANCER RESEARCH 44: 3725-3735 (2024) doi:10.21873/anticanres.17197 https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf